Idiopathic pulmonary fibrosis (IPF): Market Outlook and Competitive Landscape Report (2020 to 2030)

LAPS Triple Agonist (HM15211) of Hanmi Pharmaceutical has granted Orphan drug designation for treating Idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis occurs in the interstitium, which is the lung tissue that provides the scaffolding for the alveoli. Fibrosis thickens the interstitium, making the alveoli stiff so that they are unable to fully expand and hold as much air as they normally should. This thickening also limits the passage of oxygen through the wall of the alveoli into the bloodstream.

Based on strong domain and business knowledge Thelansis Knowledge Partners has published the market insight report on idiopathic pulmonary fibrosis (IPF) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030. Based on the Epidemiology study of Thelansis 330,056 patients are prevalent in 8 Major Markets (USA, EU5, Japan and China), out of which 183,924 patients will able to meet the treatment for the year 2021 for the same 8 major markets. Yet, there is extensive research is ongoing to come with therapies to bring ease in the IPF’s patients life. Thelansis forecasting team project the IPF market of 8 MM approx. USD 2.93 Bn for the year 2021 which expected to grow with a 9% CAGR to reach USD 7.23 Bn by the year 2030.

The Idiopathic pulmonary fibrosis (IPF) market insight report provides a comprehensive view of disease events, severity, identified and emerging biomarkers, Clinical Manifestations, progression, signs & symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines with respect to different lines of therapy at country level. Comprehensive insight on patient segmentation based on mild, moderate and severity. Based on acute, chronic comorbid condition (Pulmonary, cardiovascular, Gastrointestinal, Endocrine/Metabolic and Mental problems), IPF patients distributions among age groups 6 to 10; 11 to 15; 16 to 20; 21 to 30; 31 to 40; 41 to 50; 51 to 60; 61 to 70; 71 to 80; and 81 has been provided into the epidemiology section of the study. However the current treatment market share, market uptake, attribute analysis with respect to the 16 most potential emerging therapies (Pemrevlumab, KD025, PRM151, Tipelukast, CC 90001, PBI-4050, TD139, GLPG 1690, GLPG 1205, VAY 736, TAS-115, ART-123, LT-1001, LT-1002, INOpulse, BMS 986263) has been provided under the market outlook section of the study covering 8 MM countries; the United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, there are several pharmaceutical products are being approved as well as under different phases of development for the treatment. The key companies in to advance stage of developments are Roche, MediciNova, Galecto Biotech, Liminal BioSciences, Sanofi, Biogen, Fibrogen, Galapagos, Kadmon Corporation, Afferent Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Vicore Pharma, Bristol-Myers Squibb, Pliant Therapeutics, Novartis, Asahi Kasei Pharma, etc. targeting Idiopathic pulmonary fibrosis (IPF). Looking at the current clinical development and assets progress card, fast development and robust product would bring a game-changing opportunity for the pharmaceutical company developing products around the treatment of IPF.

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published report across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial result throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Contact Us:
clientsupport@thelansis.com
+91(124) 404-1731
www.thelansis.com

Gold Souk Mall, SECTOR 43, PHASE- 1, Gurugram, Haryana, India

Thelansis is a global Consulting and Market Research Report Company. Thelansis provides advisory services and top-quality market research solutions to Pharma and Biotech companies worldwide. We provide assistance on the entire spectrum of Healthcare Value-Chain ranging from assisting clients on asset prioritizations to sales optimization and life-cycle management.

Thelansis have an exceptional team of professionals operating from our corporate offices in the US and operational center based out of India. Our management team is passionate about building an organization that is known for the best-in-class business solutions. Our experience ranges from working with emerging Biotech to Blue-Chip Pharma Companies. Thelansis’ commitment reflects in every single project and market research report we work upon and we take pride in all the direct and in-direct contributions we make to our client’s revenue.

This release was published on openPR.